Participated · Series B · Apr 2023

SentiAR develops augmented reality visualization technology for medical procedures, centered on its CommandEP product that creates real-time 3D holographic views of patient anatomy. CommandEP integrates existing imaging systems and uses a headset to provide hands-free manipulation of patient data and live catheter locations during cardiac ablation. The system gives physicians a 360-degree interactive view of heart anatomy and has been shown to improve navigation accuracy in the heart by up to 50%. The company says the new funding will support additional partnerships and wider clinical deployments of CommandEP. SentiAR is based in St. Louis, Missouri, and positions its technology as a workflow-friendly AR tool designed not to impede clinical procedures. The company highlights clinical and strategic collaborations as central to its commercialization plans. SentiAR develops a mixed-reality visualization platform for use during interventional procedures, beginning with cardiac ablation and treatment of atrial fibrillation. Its FDA 510(k) cleared CommandEP system receives imaging data from electroanatomic mapping systems and creates a 3D holographic image via proprietary data-flow and visualization algorithms. The patented system displays real-time catheter positions in the patient’s heart through a wearable headset and relies on a custom AR engine for performance. SentiAR’s technology was spun out of Washington University in St. Louis by Dr. Jennifer Silva and Dr. Jonathan Silva. Led by CEO Berk Tas, the company plans to use new funding to accelerate innovation on the CommandEP system.

Participated · Series B · Aug 2022

ATLAS Space Operations offers Ground Station as a Service (GaaS) and Ground Software as a Service (GSaaS) through its proprietary Freedom® software, enabling unified access to a federated network of antennas. The company operates over 50 antennas across more than 34 ground stations and supports LEO, MEO, and GEO orbits for commercial, civil, and defense customers. Freedom® software centralizes antenna networks, automates communications, enables dynamic scheduling, and provides near real-time troubleshooting and rapid onboarding. ATLAS reports a 100% contract renewal rate, underscoring heavy customer reliance on its ground infrastructure. Founded in 2015, the company moved its headquarters to Traverse City, Michigan in 2017 and maintains an office in Colorado Springs, Colorado. Management cites plans to use new capital to meet rising industry demand and to execute U.S. and EMEA expansion strategies. ATLAS Space Operations provides Ground Software as a Service (G-SaaS) through its Freedom™ software platform and a global antenna network to integrate disparate ground station networks for government and commercial clients. The company positions its Freedom™ solution as an industry-disruptive software layer that federates networks and maximizes ground-station value. ATLAS plans to accelerate international growth and expand its team to deliver enterprise-level G-SaaS for commercial customers and the DoD Hybrid Space Architecture. The company intends to increase market share in the private sector while supporting government requirements. ATLAS has been recognized by the World Teleport Association as one of the top three fastest-growing teleport operators worldwide for the past two years and was named the 15th fastest-growing software company in 2020 by Inc. 5000. Its mission statement is to connect humanity through space by combining software and a global antenna network.

Participated · Series C · Sep 2021

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Led · Series A · Sep 2021

Founded in 2018, Washington-DC–based Sorcero offers an Agentic AI platform—comprising Sorcero Medical, SciComms, Safety and Medtech—that is specifically trained on life-science data and built to meet stringent regulatory and privacy requirements. The system unifies hundreds of global data sources to create a 360° view of more than 40 million healthcare professionals and 100 million scientists, enabling customers to analyze 263 million publications and 1.3 billion citations for real-time insights. One-third of the top 30 global pharmaceutical firms use Sorcero, achieving up to 92 % productivity gains in evidence generation, 72 % faster insight discovery, and publication timelines shortened by two to five months. The platform delivers 96.1 % clinical inclusion accuracy—exceeding FDA regulatory thresholds and PhD-level human performance. Sorcero’s offerings support medical affairs, safety, scientific communications, and medical devices, and are available directly and through channels such as the Google Cloud Marketplace and NIH STRIDES. Recent strategic moves include the acquisition of Axiom Health to bolster its med-device capabilities and partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake. With a cumulative $59 million raised, the company plans to scale globally and further develop its insight-driven engagement model for precision medicine.

Participated · Series A · Jun 2021

xCures builds the Clinical Clarity Engine to aggregate, extract and structure fragmented patient medical records into decision-ready clinical data delivered via a web UI or developer API. The technology was developed over nearly a decade in oncology and is now used across clinical domains and workflows. xCures reports it has processed over 300 million medical records sourced from more than 550,000 healthcare locations, supporting clinical decisions for millions of patients across the U.S. The company links every extracted answer to its source document to enable traceable, evidence-grade decisions. Financially, xCures has raised more than $76 million in total funding following the $46 million Series B. The company plans to use the new capital to accelerate product development, expand its team, and scale adoption across provider, value-based care, diagnostics lab, and consumer health customers.